OpenEvidence monetizes physician attention
OpenEvidence at $50M/year growing 30% MoM
OpenEvidence turned clinical reference from a hospital budget line into an attention business. UpToDate gets bought seat by seat through procurement, while OpenEvidence gets adopted doctor by doctor because it is free, then sells pharma access to the exact moment a physician is researching a diagnosis, drug, or treatment. That swaps slow enterprise sales for bottom up usage, and it makes each search both a product interaction and an ad impression.
-
The workflow is simpler than legacy reference tools. A verified clinician types a natural language question, gets a synthesized answer with citations, and stays inside one search box instead of opening long review articles. OpenEvidence built trust and data depth by signing multi year content deals with NEJM in February 2025 and JAMA in June 2025.
-
The money model looks more like Doximity than UpToDate. Doximity has already shown pharma will pay premium rates for physician attention at scale, reaching more than 80% of U.S. doctors. OpenEvidence pushes that logic further because the ad appears during active clinical research, which is a much higher intent moment than scrolling a professional newsfeed.
-
This also changes who controls distribution. UpToDate still has deep institutional reach, with more than 2 million users globally and expanding AI features inside enterprise products. But free access let OpenEvidence spread across more than 10,000 care sites and over 40% of U.S. physicians before asking hospitals to buy anything.
The next step is to convert search traffic into a broader physician operating system. As OpenEvidence adds notes, calling, calculators, and EHR connected workflows, it can keep the free entry point that drove adoption while layering enterprise products and more ad inventory on top. That path points toward taking share not just from UpToDate, but from the wider stack of doctor tools around daily care.